UNITED STATES




SECURITIES AND EXCHANGE COMMISSION




WASHINGTON, D.C. 20549




FORM 10-Q/A




xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES




EXCHANGE ACT OF 1934




For the quarterly period ended June 30, 2009




 ̈ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES




EXCHANGE ACT OF 1934




For the transition period from __________ to __________




COMMISSION FILE NUMBER 000-51334


HEMOBIOTECH, INC.


(Exact name of Registrant as Specified in Its Charter)





Delaware
33-0995817(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)5001 Spring Valley Rd, Suite 1040 - West, Dallas, Texas 75244(Address of principal executive offices and Zip Code)(972) 455-8950(Registrant's telephone number, including area code)




Identify by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.




Yes x No  ̈


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files).


Yes o   No o




Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one).




Large accelerated filer    ̈                                                                                                                          Accelerated
Filer    ̈




Non-accelerated filer  ̈                                                      (Do
not check if a smaller reporting company.)   Smaller reporting company   x




Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ̈ No x




As of August 18, 2009, the registrant had outstanding 21,192,600 shares of common stock, $0.001 par value per share.








EXPLANATORY NOTE
   This Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2009 (the “Form 10-Q”), originally filed by HemoBioTech, Inc. on August 18, 2009 is being filed solely for the purpose of adding disclosure under "Item 4. Submission of Matters to a Vote of Security Holders" in Part II of the Form
10-Q.
   Exhibit 31.1 and Exhibit 31.2 are also filed herewith.
   Except as described above, no other changes have been made to this Form 10-Q. This Amendment does not amend, update or change the financial statements or disclosures in the Form 10-Q and does not reflect events occurring after the filing of the Form 10-Q.
   1
    PART II -- OTHER INFORMATION


ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
 At our annual meeting of stockholders held June 4, 2009, the following matters were submitted to a vote:
 
 1.  The election of the following persons as directors for a one-year term:
  Name
Votes For
Votes WithheldArthur P. Bollon, Ph.D.
12,820,358
145,947Ghassan Nino, CPA, CMA
12,820,358
145,947Robert Comer, CPA, M.B.A
12,820,358
145,947Robert Baron
12,820,358
145,947Lt. General Bernhard Mittemeyer, M.D
12,820,358
145,947
  2.  The  ratification  of the  appointment  of  Eisner  LLP  as our  independent registered public accounting firm for the fiscal yaer ending December 31, 2009:
  Votes For                               Against             Abstain
  12,800,426                              165,879              0
   ITEM 6. EXHIBITS
 
 Exhibit No.
Description31.1
Certification of Principal Executive Officer required under Rule 13a-14(a) or Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended.31.2
Certification of Principal Financial Officer required under Rule 13a-14(a) or Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended.
    2
   SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
  HEMOBIOTECH, INC.
  
 Date: August 27, 2009
By:
/s/ ARTHUR P. BOLLON, PH.D.Arthur P. Bollon, Ph.D.Chairman of the Board of Directors, President and Chief Executive OfficerDated: August 27, 2009
By:
/s/ MARK J. ROSENBLUMMark J. RosenblumChief Financial Officer and Secretary
 
   3